10 Best All-Time High Stocks to Buy According to Wall Street

Page 1 of 3

Wall Street’s leadership changed hands over the past month. The technology and chip stocks that carried the market through most of 2026 lost ground, while healthcare, financials, real estate, utilities and consumer-focused stocks took over.

The scoreboard showed it in mid-October. Healthcare led gains among the S&P 500’s 11 sectors and hit a record high, financials rose 1%, real estate climbed 1.7% and utilities added 1.2%, while technology slipped 0.3%. The S&P 500 value index gained 0.9% that day as its growth counterpart dipped 0.2%. Jim Baird, chief investment officer at Plante Moran Financial Advisors, tied the move to doubts about AI payoffs: “Investors are looking for other opportunities outside of tech, and healthcare is one of the beneficiaries of that.”

Tech’s Slide Hands Leadership to Defensive Sectors

The rotation sped up in November. On Monday, investors moved into consumer cyclical, financial services and consumer defensive stocks, and the main technology sector fund was down 2.4% by mid-afternoon. Last Thursday, the Philadelphia Semiconductor Index fell as much as 11%, its worst showing since March 2020, and the Nasdaq Composite slid into a correction, a drop of at least 10% from its record close in early October. The VIX, Wall Street’s fear gauge, jumped more than 65% in a day. In short, money moved toward companies with steadier earnings and away from the most crowded trades.

Sameer Samana, senior global market strategist at Wells Fargo Investment Institute, said the pain was concentrated: “Anything related to AI is down more than anything not related to AI.” Our ranking of stocks sitting near all-time highs that Wall Street favors looks at names that have held up through the swings.

Why Strategists See a Handoff From Growth to Cash Flow

Samana described the shift as a change of buyers. The first wave of AI investors chased growth, he said, while a newer group wants companies with healthy cash flow, and he noted that many AI stocks are still not cheap. Will Compernolle, a macro strategist at FHN Financial, said the selling in chipmakers was sending money into Treasuries, and that investors were also rotating from chipmakers into the biggest spenders on AI data centers.

We covered the group that led October’s gains in our list of healthcare stocks that hedge funds favor. Not everyone reads the selloff as a verdict on the economy. Charlie McElligott, a cross-asset strategist at Nomura, said it reflected hedge funds locking in their 2026 gains rather than a worsening in fundamentals.

Charts

Our Methodology

For this article, we used Finviz to screen for companies with market capitalizations above $2 billion whose stocks are at new all-time highs. We then ranked them by average upside potential, based on analysts’ average price target, in ascending order, as of November 9, 2026. We also list each stock’s number of hedge fund holders as of Q2 2026, from our database of 1,006 hedge funds.

At Insider Monkey, we are obsessed with what hedge funds do. The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter strategy selects 14 small-cap and large-cap stocks every quarter and has returned 612% since May 2014, beating its benchmark by 375 percentage points (see more details here).

10 Best All-Time High Stocks to Buy According to Wall Street

10. Labcorp (NYSE:LH)

Average Upside Potential: 7%

Share Price: $366.57

Target Price: $392.93

Number of Hedge Fund Holders: 43

Labcorp’s profit is growing about twice as fast as its sales, and management raised its outlook again after the third quarter. Revenue rose 6.9% from a year earlier, while adjusted earnings per share climbed 14.5%. Chairman and Chief Executive Officer Adam Schechter pointed to continued margin expansion behind the gap. The gap shows the gains are not coming from volume alone: the company is keeping more of each dollar it brings in.

The lab operator is also buying more testing volume. It closed its purchase of MLM Medical Labs in the quarter. Since then it has signed agreements to take select BioReference Health lab assets, Myriad Genetics’ prenatal health testing business and Millennium Health, each still waiting on regulatory approval. Cash is paying for much of this: free cash flow came to $412.2 million, up from $280.5 million a year earlier.

Management now expects 2026 adjusted earnings of $18.30 to $18.70 per share, up from a range of $18.10 to $18.55. Whether the discount is worth the cost of all that spending is the question in our look at Labcorp’s earnings discount and growing investment bill.

9. Xometry (NASDAQ:XMTR)

Average Upside Potential: 8%

Share Price: $114.95

Target Price: $124.25

Number of Hedge Fund Holders: 40

Xometry has now grown revenue about 40% for two quarters running, and this time the growth came with a profit. Chief Financial Officer James Miln noted that sales growth held at that pace for the second quarter in a row. Third-quarter revenue reached a record, led by the marketplace side, where buyers post designs for custom parts and manufacturers bid to make them. Sales that grow this fast tend to eat into profit, which is why strong growth that also pays off matters.

The turn to profit is the newer part of the story. The company reported net income of $1.9 million, against a net loss of $11.6 million a year earlier. Chief Executive Officer Sanjeev Singh Sahni said the company’s key growth initiatives drove the record results, and the marketplace’s gross margin also hit a record.

Management lifted its full-year outlook as a result. It now expects revenue growth of at least 37%, up from the 33% to 34% it forecast before, along with adjusted EBITDA of $68 million to $68.5 million for the year. Investors who followed the stock through its loss-making years now have a company that is growing and earning at once.

Page 1 of 3